Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Avonex

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Interferon beta-1a treatment reduced the rate at which high-risk individuals develop clinically definite multiple sclerosis by 44% compared to placebo, according to a study published in the Sept. 28 New England Journal of Medicine. The 383-patient study also showed that 20 mcg Avonex injected intramuscularly once a week for up to three years had "a highly significant positive impact in reducing the rate at which patients developed brain abnormalities, or lesions, visible on MRI scans" compared to placebo, according to the company. Biogen plans to apply for an expanded label to reflect this early treatment regime
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel